In vitro biotransformation of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine by mouse liver microsomes

References

• BELEJOVA, M., CHMELA, Z., RYPKA, M., LEMR, K., LUKE, J., HANu§, J., ULRICHOVA, J. and VESELY, J., 1999, Metabolism of synthetic CDK-inhibitors in mammalian cells. Paper presented at the 15th Biological Days, 6–8 September, Ceske Budejovice, Czech Republic; repr. J. Berger (ed.), Cells (Ceske Budejovice: KOOP), p. 39.
   Google Scholar
• BOOGAARDS, J. J. P., BERTRAND, M., JACKSON, P., OUDSHOORN, M. J., WEAVER, R. J., VAN BLADEREN, P. J. and WALTHER, B., 2000, Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica, 30, 1131–1152.
   Google Scholar
• BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321–332.
   PubMed Web of Science ®Google Scholar
• BUOLAMWINI, J. K., 2000, Cell cycle molecular targets in novel anticancer drug discovery. Current Pharmaceutical Design, 6, 379–392.
   PubMed Web of Science ®Google Scholar
• ERVENKOVA, K., BELEJOVA, M., CHMELA, Z., RYPKA, M., RIEGROVA, D., MicHNovA, K., MicHAOKovA, K., S'CRovA, I., BREJCHA, A., HANI.J, J., 'CERNY, B., FumovA, K., HAVLIeEK, L., VESELY, J., 2002, In vitro glycosidation potential towards olomoucine-type cyclin-dependent kinase inhibitors in rodent and primate microsomes. Physiological Research, accepted for publication.
   Google Scholar
• ERVENKOVA, K., CHMELA, Z., RYPKA, M., LEMR, K., FIANm's, J., HAVLreEK, L., BELEJOVA, M., LOTKOVA, H., CERVINKOVA, Z. and VESELY, J., 2000, Metabolism of cyclin-dependent kinase inhibitor bohemine at the cellular and subcellular levels. Paper presented at the 2nd FEPS Congress, 29 June-4 July 1999, Prague, Czech Republic; abst. Physiological Research, 49, P42.
   Google Scholar
• CHANG, Y. T., GRAY, N. S., ROSANIA, G. R., SUTHERLIN, D. P., KWON, S., NORMAN, T. C., SAROHIA, R., LEOST, M., MEIJER, L. and SCHULTZ, P. G., 1999, Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chemistry and Biology, 6, 361–375.
   PubMed Web of Science ®Google Scholar
• CHAURET, N., GAUTHIER, A., MARTIN, J. and NICOLL-GRIFFITH, D. A., 1997, In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metabolism and Disposition, 25, 1130–1136.
   PubMed Web of Science ®Google Scholar
• CHMELA, Z., VESELY, J., LEMR, K., HANU, J., HAVLieEK, L., RYPKA, M., KRY§TOF, V., ULRICHOVA, J., WALTEROVA, D., FumovA, K., LUKE, J., KoLAkovA, H., STRNAD, M. and LENOBEL, R., 1998, Metabolism of olomoucine, roscovitine, and bohemine in small laboratory rodents. Paper presented at the 1st International Conference on Inhibitors of Protein Kinases, 15–20 September, Warsaw, Poland; abst. Cellular and Molecular Biology Letters, 3, 280.
   Google Scholar
• CHMELA, Z., VESELY, J., LEMR, K., RYPKA, M., HANUE, J., HAVLIeEK, L., KRYSTOF, V., MICHNOVA, L., FuusovA, K. and LUKE'S, J., 2001, In vivo metabolism of 2,6,9-trisubstituted purine- derived cyclin-dependent kinase inhibitor bohemine in male mice: glucosidation as the principal metabolic route. Drug Metabolism and Disposition, 29, 326–334.
   Google Scholar
• COURT, M. H., VON MOLTKE, L. L., SHADER, R. I. and GREENBLATT, D. J., 1997, Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharmaceutics and Drug Disposition, 18, 213–226.
   PubMed Web of Science ®Google Scholar
• DOOSTZADEH, J., COTILLON, A.-C., BENALYCHERIF, A. and MORFIN, R., 1998a, Inhibition studies of dehydroepiandrosterone 7a- and 7t3hydroxylation in mouse liver microsomes. Steroids, 63, 608–614.
   Google Scholar
• DOOSTZADEH, J., COTILLON, A.-C. and MORFIN, R., 1998b, Hydroxylation of pregnenolone at the 7 alpha- and beta-positions by mouse liver microsomes. Effects of cytochrome p450 inhibitors and structure-specific inhibition by steroid hormones. Steroids, 63, 383–392.
   Google Scholar
• EAGLING, V. A., TJIA, J. F. and BACK, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107–114.
   PubMed Web of Science ®Google Scholar
• EPSTEIN, J., PLAPINGER, R. E., MICHEL, H. O., CABLE, J. R., STEPHANI, R. A., HESTER, R. J., BILLINGTON. C., Jr and LIST, G. R., 1964, Reactions of isopropyl methylphosphonofluoridate with substituted phenols. I. Journal of the American Chemical Society, 86, 3075–3084.
   Google Scholar
• FISCHER, P. M. and LANE, D. P., 2000, Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Current Medicinal Chemistry, 7, 1213–1245.
   PubMed Web of Science ®Google Scholar
• GALLAGHER, E. P., WIENKERS, L. C., STAPLETON, P. L., KUNZE, K. L. and EATON, D. L., 1994, Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1 . Cancer Research, 54, 101–108.
   PubMed Web of Science ®Google Scholar
• GARCIA-ECHEVERRIA, C., TRAXLER, P. and EVANS, D. B., 2000, ATP site-directed competitive and irreversible inhibitors of protein kinases. Medical Research Reviews, 20, 28–57.
   PubMed Web of Science ®Google Scholar
• GRAY, A. S., WODICKA, L., THUNNISSEN, A.-M. W. H., NORMAN, T. C., KWON, S., ESPINOZA, F. H., MORGAN, D. O., BARNES, G., LECLERC, S., MEIJER, L., Kim, S.-H., LOCKHART, D. J. and SCHULTZ, P. G., 1998, Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science, 281, 533–538.
   Google Scholar
• GRAY, N., DETIVAUD, L. and MEIJER, L., 1999, ATP-site directed inhibitors of cyclin-dependent kinases. Current Medicinal Chemistry, 6, 859–875.
   PubMed Web of Science ®Google Scholar
• GU, J., ZHANG, Q. Y., GENTER, M. B., LIPINSKAS, T. W., NEGISHI, M., NEBERT, D. W. and DING, X., 1998, Purification and characterization of heterogously expressed mouse CYP2A5 and CYP2G1: role in metabolic activation of acetaminophen and 2,6-dichlorobenzonitrile in mouse olfactory mucosal microsomes. Journal of Pharmacology and Experimental Therapeutics, 285, 1287–1295.
   PubMed Web of Science ®Google Scholar
• HAVLIEEK, L., Hsavu's, J., VESELY, J., LECLERC, S., MEIJER, L., SHAW, G. and STRNAD, M., 1997, Cytokinin- derivedcyclin dependent kinase inhibitors: synthesis and cdc2 activity of olomoucine and related compounds. Journal of Medicinal Chemistry, 40, 408–412.
   Google Scholar
• HICKMAN, D., WANG, J. P., WANG, Y. and UNADKAT, J. D., 1998, Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monoxygenase activities. Drug Metabolism and Disposition, 26, 207–215.
   PubMed Web of Science ®Google Scholar
• HOCART, C. H., LETHAM, D. S. and PARKER, C. W., 1991, Substituted xanthines and cytokinin analogues as inhibitors of cytokinin N-glucosylation. Phytochemistry, 30, 2477–2486.
   Google Scholar
• HONDA, A., SALEN, G., MATSUZAKI, Y., BATTA, A. K., Xu, G., LEITERSDORF, E., TINT, G. S., ERICKSON, S. K., TANAKA, N. and SHEFER, S., 2001, Side chain hydroxylations in bile acid biosynthesis catalyzed by CYP3A are markedly up-regulated in Cyp27—/— mice but not in cerebrotendinous xanthomatosis. Journal of Biological Chemistry, 276, 34579–34585.
   PubMed Web of Science ®Google Scholar
• JONES, E. C. S. and PYMAN, F. L., 1925, The relation between chemical constitution and pungency in acid amides. Journal of the Chemical Society, 127, 2588–2598.
   Google Scholar
• JUVONEN, R. O., GYNTHER, J., PASANEN, M., ALHAVA, E. and Poso, A., 2000, Pronounced differences in inhibition potency of lactone and non-lactone compounds for mouse and human coumarin 7-hydroxylases (CYP2A5 and CYP2A6). Xenobiotica, 30, 81–92.
   PubMed Web of Science ®Google Scholar
• LEGRAVEREND, M., LUDWIG, O., BISAGNI, E., LECLERC, S., MEIJER, L., GIOCANTI, N., SADRI, R. and FAVAUDON, V., 1999, Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin- dependent kinase inhibitors. Bioorganic and Medicinal Chemistry, 7, 1281–1293.
   PubMed Web of Science ®Google Scholar
• MEIJER, L., 2000, Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents. Drug Resistance Updates, 3, 83–88.
   PubMedGoogle Scholar
• MEIJER, L., LECLERC, S. and LEOST, M., 1999, Properties and potential applications of chemical inhibitors of cyclin-dependent kinases. Pharmacology and Therapeutics, 82, 279–284.
   PubMed Web of Science ®Google Scholar
• MICHALiKOVA, K., MicimovA, L., BELEJOVA, M., CHMELA, Z., RYPKA, M., LEMR, K., HAvOau, L., LUKE, J., VESELY, J. and ULRICHOVA, J., 1999, Enzyme systems involved in metabolism of purine-related cyclin-dependent kinase inhibitors. Paper presented at the 15th Biological pays, 6-8 September, Ceske Budejovice, Czech Republic; abst. J. Berger (ed.), Cells (Ceske Budejovice: KOOP), p. 97.
   Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors. Evaluation of specifities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• OTYEPKA, M., KRY'STOF, V., HAVLieEK, L., Im,ssovA, V., STRNAD, M. and Koet., J., 2000, Docking-based development of purine-like inhibitors of cyclin- dependent kinase-2. Journal of Medicinal Chemistry, 43, 2506–2513.
   Google Scholar
• PATTEN, C. J., PETERSON, L. A. and MURPHY, S. E., 1998, Evidence for metabolic activation of N-nitrosonornicotine and N-nitrosobenzyl methylamine by rat nasal coumarin hydroxylase. Drug Metabolism and Disposition, 26, 177–180.
   PubMedGoogle Scholar
• PELKONEN, O., MAENPAA, J., TAAVITSAINEN, P., RAUTIO, A. and RAUNIO, H., 1998, Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica, 28, 1203–1253.
   PubMed Web of Science ®Google Scholar
• QUINTIERI, L., ROSATO, A., NAPOLI, E., SOLA, F., GERONI, C., FLOREANI, M. and ZANVELLO, P., 2000, In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A. Cancer Research, 60, 3232–3238.
   PubMed Web of Science ®Google Scholar
• RAIFORD, L. C. and CLARK, E. P., 1923, Diacyl derivatives of ortho-hydroxybenzylamine. Journal of the American Chemical Society, 45, 1738–1743.
   Google Scholar
• RENDIC, S., 2002, Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews, 34, 83–448.
   PubMed Web of Science ®Google Scholar
• ROSANIA, G. R. and CHANG, Y.-T., 2000, Targeting hyperproliferative disorders with cyclin-dependent kinase inhibitors. Expert opinion on Therapeutic Patents, 10, 215–230.
   Google Scholar
• SAUSVILLE, E. A., ZAHAREVITZ, D., Gussto, R., MEIJER, L., LOUARN-LEOST, M., KUNICK, C., SCHULTZ, R., LAHUSEN, T., HEADLEE, D., STINSON, S., ARBUCK, S. G. and SENDEROVICZ, A., 1999, Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacology and Therapeutics, 82, 285–292.
   Google Scholar
• SIELECKI, T. M., BOYLAN, J. F., BENELD, P. A. and TRAINOR, G. L., 2000, Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. Journal of Medicinal Chemistry, 43, 1–18.
   PubMed Web of Science ®Google Scholar
• VENKATAKRISHNAN, K., VON MOLTKE, L. L. and GREENBLATT, D. J., 2001. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. Journal of Clinical Pharmacology, 41, 1149–1179.
   PubMed Web of Science ®Google Scholar
• VESELY J., HAvLiCsx, L., STRNAD, M., BLOW, J. J., DONELLA-DEANA, A., PINNA, L., LETHAM, D. S., KATO, J., DETIVAUD, L., LECLERC, S. and MEIJER, L., 1994, Inhibition of cyclin-dependent kinases by purine analogues. European Journal of Biochemistry, 224, 771–786.
   Google Scholar
• WILSON, W. S. and LEBLANC, G. A., 2000, The contribution of hepatic inactivation of testosterone to the lowering of serum testosterone levels by ketoconazole. Toxicological Sciences, 54, 128–137.
   PubMed Web of Science ®Google Scholar